AnaptysBio, Inc.
ANABHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, AnaptysBio, Inc. (ANAB) is listed under Biotechnology. The company carries a $1.68B market cap, placing it firmly in the small-cap category. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Market Cap
$1.68B
Beta
0.41
P/E (TTM)
—
P/E (Fwd)
10.85
EPS (TTM)
$-1.02
EPS (Fwd)
$5.24
ROE
-114.5%
ROA
6.8%
Cash
$286.5M
Total Debt
$277.4M
Free CF
$8.3M
52W Change
284.0%
Annual Financials
Cash vs Debt
Where ANAB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ANAB finished 8.43% above its 150-day moving average ($51.50) and 21.13% above its 200-day moving average ($46.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANAB overbought or oversold?
At the September 3, 2026 close, ANAB's RSI(14) was 49.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
AnaptysBio, Inc. holds $286.5M in cash against $277.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $8.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -114.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $63.2M (2021) to $234.6M (2025), reflecting a 271% increase over the period.
The relatively low beta of 0.41 suggests ANAB is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AnaptysBio, Inc. and its sector.